Cellerys

Cellerys, a 2019 spin-off from the University of Zurich, is pioneering antigen-specific tolerance induction therapies for autoimmune diseases, starting with multiple sclerosis. Its innovative approach uses autologous red blood cells coupled with peptides to re-establish immune tolerance, differentiating it from non-specific immunosuppressive drugs. The company has successfully completed a Phase Ib trial (RED4MS) with Novartis and is preparing for a Phase IIa study, backed by a leadership team with deep expertise in neuroimmunology and MS research.

Antigen-specific T-cell tolerance induction platform using autologous red blood cells coupled with disease-specific peptides to reprogram or delete autoreactive T-cells.

Cellerys competes in the crowded MS market dominated by broad immunosuppressants but occupies a unique niche focused on antigen-specific tolerance. Direct competitors are few but include other companies developing tolerogenic therapies (e.g., using peptide or DNA platforms). Its partnership with Novartis provides a significant strategic advantage in resources and development expertise.